The Quantellect read.As of Nov 19, 2026, 13 active firms cover Janux Therapeutics Inc: 10 rate it Buy or better, 2 sit at Neutral, and 1 rate it Sell or worse, a buy consensus. Targets range widely, $23.00 to $55.00 (about 2.4x), a sign of real disagreement on valuation. The average target of $33.20 sits 222% above the current $10.31. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.56 next quarter toward $-2.55 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS13 active firms
Buy
Strong Buy00%
Buy1077%
Neutral215%
Sell18%
Strong Sell00%
Based on 13 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$33.20
+222.0% upside
Average target across 5 active firms as of Nov 19, 2026 vs $10.31 current
Highest Target$55.00
Average Target$33.20
Lowest Target$23.00
Detailed analyst forecasts for JANX
Showing 1–5 of 5 named analysts shown · 13 active firms in the rating projection
As of Nov 19, 2026, 10 of 13 active firms rate JANX a Buy (2 Neutral, 1 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
JANX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.56
Range $-0.66 – $-0.43 · 7 analysts · +45% YoY
Next period, 7 analysts expect Janux Therapeutics Inc to earn $-0.56 a share (range $-0.66 – $-0.43), versus $-0.39 a year earlier. Full-year consensus is $-1.57, growing to $-2.55 the year after.
REVENUE · NEXT QUARTER
$2.3M
Range $0 – $7.6M · 7 analysts · -37% YoY
Revenue is expected to reach $2.3M (range $0 – $7.6M), -37.4% year-over-year. Full-year consensus is $27.5M, rising to $7.6M next year.
Top analysts covering Janux Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on JANX.
#1
George Farmer
Scotiabank · Rank #311
Neutral
$36.00+249.2% to target
Overall win rate
44%
+ Follow
#2
Swayampakula Ramakanth
HC Wainwright & Co. · Rank #321
Buy
$45.00+336.5% to target
Overall win rate
38%
+ Follow
#3
SW
Stephen Willey
Stifel · Rank #474
Buy
$35.00+239.5% to target
Overall win rate
29%
+ Follow
#4
Robert Driscoll
Wedbush · Rank #490
Buy
$40.00+288.0% to target
Overall win rate
32%
+ Follow
#5
Justin Zelin
BTIG · Rank #495
Buy
$100.00+869.9% to target
Overall win rate
30%
+ Follow
JANX stock forecast FAQ
What is JANX's average 12-month price target?+
The 5 active firms with a live target average $33.20 for Janux Therapeutics Inc over the next 12 months, ranging from a $55.00 high to a $23.00 low, as of Nov 19, 2026.
Is JANX stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 13 active firms as of Nov 19, 2026, 10 rate it Buy or Strong Buy, 2 rate it Neutral, and 1 rate it Sell or Strong Sell.
What are the highest and lowest price targets for JANX?+
The Street-high target is $55.00 (Guggenheim), and the Street-low is $23.00 (Wolfe Research). The average of all 5 active-firm targets is $33.20.
How many active Wall Street firms cover JANX?+
13 active firms have a recognized rating on Janux Therapeutics Inc as of Nov 19, 2026, and 5 active firms carry a live 12-month price target.
Who is the most accurate analyst covering JANX?+
Among analysts who currently cover JANX, George Farmer of Scotiabank has the strongest overall Quantellect track record (Rank #311). Their current call is Neutral with a $36.00 target.
What is Janux Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.56 per share (range $-0.66 – $-0.43) across 7 analysts. Full-year EPS is projected at $-1.57, rising to $-2.55 the following year.
How much revenue is Janux Therapeutics Inc expected to report next quarter?+
Consensus revenue is $2.3M (range $0 – $7.6M). Full-year revenue is projected at $27.5M, growing to $7.6M next year.
Have analysts been upgrading or downgrading JANX lately?+
As of Nov 19, 2026, 10 of 13 active firms rate JANX a Buy (2 Neutral, 1 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their JANX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.